bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Methods from In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models
Authors: Cornillie Jasmien , Wozniak Agnieszka , Pokreisz Peter , Casazza Andrea , Vreys Lise , Wellens Jasmien , Vanleeuw Ulla , Gebreyohannes Yemarshet K. , Debiec-Rychter Maria , Sciot Raf , Hompes Daphne , Schöffski Patrick
Published: April 2023

Details on the synthetic method to make PhAc-ALGP-doxorubicin
Supplementary Figure S1-S8 from APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer
Authors: Tanaka Noritaka , Mashima Tetsuo , Mizutani Anna , Sato Ayana , Aoyama Aki , Gong Bo , Yoshida Haruka , Muramatsu Yukiko , Nakata Kento , Matsuura Masaaki , Katayama Ryohei , Nagayama Satoshi , Fujita Naoya , Sugimoto Yoshikazu , Seimiya Hiroyuki
Published: April 2023

Supplementary Figure S1: Full scans of the immunoblots shown in Figs. 1C, 2A and 4A. Supplementary Figure S2: Basal expression of tankyrase, Axins, and β-catenin and intracellular localization of β-catenin in CRC cell lines used in this study. Supplementary Figure S3: Response of colorectal cancer SW480 cells to tankyrase inhibitors. Supplementary Figure S4: Depletion of long APC enhances β-catenin signaling and restores tankyrase inhibitor-mediated downregulation of the signal. Supplementary Figure S5: Long but not short APC represses Wnt/β-catenin signal and its knockdown sensitizes β-catenin to tankyrase inhibitor-mediated downregulation. Supplementary Figure S6: Schematic models for the differential effects of the "short" and "long" APC mutants on tankyrase inhibitor (TNKSi)-mediated downregulation of β-catenin. Supplementary Figure S7: APC mutations and sensitivity to tankyrase inhibitors of the patient-derived CRC cells. Supplementary Figure S8: Effects of a tankyrase inhibitor G007-LK on colony formation and β-catenin knockdown on proliferation of patient-derived CRC cells (PDCs).
Figure S3 from In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models
Authors: Cornillie Jasmien , Wozniak Agnieszka , Pokreisz Peter , Casazza Andrea , Vreys Lise , Wellens Jasmien , Vanleeuw Ulla , Gebreyohannes Yemarshet K. , Debiec-Rychter Maria , Sciot Raf , Hompes Daphne , Schöffski Patrick
Published: April 2023

Evolution of relative tumor volume of each of the six tumors entered in the UZLX-STS7 regrowth experiment.
Figure S2 from In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models
Authors: Cornillie Jasmien , Wozniak Agnieszka , Pokreisz Peter , Casazza Andrea , Vreys Lise , Wellens Jasmien , Vanleeuw Ulla , Gebreyohannes Yemarshet K. , Debiec-Rychter Maria , Sciot Raf , Hompes Daphne , Schöffski Patrick
Published: April 2023

Immunohistochemical analysis of the metabolizing enzymes thimet oligopeptidase (TOP) and CD26 in tumors of UZLX-STS3 (as positive controls) and untreated murine heart and liver sections. Images of immunostainings were captured under 400-fold magnification.
Supplementary Figure Legends from APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer
Authors: Tanaka Noritaka , Mashima Tetsuo , Mizutani Anna , Sato Ayana , Aoyama Aki , Gong Bo , Yoshida Haruka , Muramatsu Yukiko , Nakata Kento , Matsuura Masaaki , Katayama Ryohei , Nagayama Satoshi , Fujita Naoya , Sugimoto Yoshikazu , Seimiya Hiroyuki
Published: April 2023

Legends for Supplementary Figure S1-S8
Supplementary Materials and Methods from The T197A Knock-in Model of Cdkn1b Gene to Study the Effects of p27 Restoration In Vivo
Authors: De Marco Carmela , Rinaldo Nicola , De Vita Fernanda , Forzati Floriana , Caira Elvira , Iovane Valentina , Paciello Orlando , Montanaro Donatella , D'Andrea Sara , Baldassarre Gustavo , Papparella Serenella , Malanga Donatella , Baldi Alfonso , Viglietto Giuseppe
Published: April 2023

The file contains a detailed description of the generation of the Cdkn1b T197A/T197A mice
Figure S4 from The T197A Knock-in Model of Cdkn1b Gene to Study the Effects of p27 Restoration In Vivo
Authors: De Marco Carmela , Rinaldo Nicola , De Vita Fernanda , Forzati Floriana , Caira Elvira , Iovane Valentina , Paciello Orlando , Montanaro Donatella , D'Andrea Sara , Baldassarre Gustavo , Papparella Serenella , Malanga Donatella , Baldi Alfonso , Viglietto Giuseppe
Published: April 2023

The figure describes the effects of BAY 11-7082 on cell proliferation in the organs from Cdkn1b WT/WT and Cdkn1b T197A/T197A mice
Figure S2 from The T197A Knock-in Model of Cdkn1b Gene to Study the Effects of p27 Restoration In Vivo
Authors: De Marco Carmela , Rinaldo Nicola , De Vita Fernanda , Forzati Floriana , Caira Elvira , Iovane Valentina , Paciello Orlando , Montanaro Donatella , D'Andrea Sara , Baldassarre Gustavo , Papparella Serenella , Malanga Donatella , Baldi Alfonso , Viglietto Giuseppe
Published: April 2023

The figure reports the Tunel staining of tissues from Cdkn1b WT/WT and Cdkn1b T197A/T197A mice
Supplementary Figure S1 from Inhibition of Heparanase in Pediatric Brain Tumor Cells Attenuates their Proliferation, Invasive Capacity, and In Vivo Tumor Growth
Authors: Spyrou Argyris , Kundu Soumi , Haseeb Lulu , Yu Di , Olofsson Tommie , Dredge Keith , Hammond Edward , Barash Uri , Vlodavsky Israel , Forsberg-Nilsson Karin
Published: April 2023

Combinatorial effect of PG545 and conditioned medium (CM) on cell viability, and examination of apoptosis after downregulation of HPSE
Legends from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
Authors: Zanini Elisa , Louis Louay S. , Antony Jane , Karali Evdoxia , Okon Imoh S. , McKie Arthur B. , Vaughan Sebastian , El-Bahrawy Mona , Stebbing Justin , Recchi Chiara , Gabra Hani
Published: April 2023

Supplementary figures legend
Supplementary Materials and Methods from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Authors: Totiger Tulasigeri M. , Srinivasan Supriya , Jala Venkatakrishna R. , Lamichhane Purushottam , Dosch Austin R. , Gaidarski Alexander A. , Joshi Chandrashekhar , Rangappa Shobith , Castellanos Jason , Vemula Praveen Kumar , Chen Xi , Kwon Deukwoo , Kashikar Nilesh , VanSaun Michael , Merchant Nipun B. , Nagathihalli Nagaraj S.
Published: April 2023

Supplementary Materials and Methods
Figure S4 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
Authors: Zanini Elisa , Louis Louay S. , Antony Jane , Karali Evdoxia , Okon Imoh S. , McKie Arthur B. , Vaughan Sebastian , El-Bahrawy Mona , Stebbing Justin , Recchi Chiara , Gabra Hani
Published: April 2023

Total protein controls
Supplementary Figure S6 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Authors: Totiger Tulasigeri M. , Srinivasan Supriya , Jala Venkatakrishna R. , Lamichhane Purushottam , Dosch Austin R. , Gaidarski Alexander A. , Joshi Chandrashekhar , Rangappa Shobith , Castellanos Jason , Vemula Praveen Kumar , Chen Xi , Kwon Deukwoo , Kashikar Nilesh , VanSaun Michael , Merchant Nipun B. , Nagathihalli Nagaraj S.
Published: April 2023

Supplementary Figure S6 shows body weight of PKT mice and xenograft mice.
Figure S2 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
Authors: Zanini Elisa , Louis Louay S. , Antony Jane , Karali Evdoxia , Okon Imoh S. , McKie Arthur B. , Vaughan Sebastian , El-Bahrawy Mona , Stebbing Justin , Recchi Chiara , Gabra Hani
Published: April 2023

SKOV3, OV90 and SKBR3 cells express different amounts of ErbB receptors
Supplementary Figure S4 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Authors: Totiger Tulasigeri M. , Srinivasan Supriya , Jala Venkatakrishna R. , Lamichhane Purushottam , Dosch Austin R. , Gaidarski Alexander A. , Joshi Chandrashekhar , Rangappa Shobith , Castellanos Jason , Vemula Praveen Kumar , Chen Xi , Kwon Deukwoo , Kashikar Nilesh , VanSaun Michael , Merchant Nipun B. , Nagathihalli Nagaraj S.
Published: April 2023

Supplementary Figure S4 shows AKT knockdown analysis, K8484 cells analyzed for PDK1, pGSK3β and p4E-BP1 levels with Uro A treatment, and AKT activator SC79 with Uro A treatment on cell proliferation.
Figure S1 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
Authors: Zanini Elisa , Louis Louay S. , Antony Jane , Karali Evdoxia , Okon Imoh S. , McKie Arthur B. , Vaughan Sebastian , El-Bahrawy Mona , Stebbing Justin , Recchi Chiara , Gabra Hani
Published: April 2023

Schematic view of the constructs used in the mammalian 2-hybrid assays
Supplementary Figure S2 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Authors: Totiger Tulasigeri M. , Srinivasan Supriya , Jala Venkatakrishna R. , Lamichhane Purushottam , Dosch Austin R. , Gaidarski Alexander A. , Joshi Chandrashekhar , Rangappa Shobith , Castellanos Jason , Vemula Praveen Kumar , Chen Xi , Kwon Deukwoo , Kashikar Nilesh , VanSaun Michael , Merchant Nipun B. , Nagathihalli Nagaraj S.
Published: April 2023

Supplementary Figure S2 shows cell apoptosis and cell cycle analysis after Uro A treatment in PDAC cells.
Supplementary Data from Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs
Authors: Currier Mark A. , Stehn Justine R. , Swain Ashleigh , Chen Duo , Hook Jeff , Eiffe Eleanor , Heaton Andrew , Brown David , Nartker Brooke A. , Eaves David W. , Kloss Nina , Treutlein Herbert , Zeng Jun , Alieva Irina B. , Dugina Vera B. , Hardeman Edna C. , Gunning Peter W. , Cripe Timothy P.
Published: April 2023

Supplementary Materials and Methods; Figure S1. Western blot of tropomyosin isoforms in neuroblastoma cells used in this project; Figure S2. Effect of combining tropomyosin and microtubule inhibitors on cell growth; Figure S3. A, B, Effect of TR100 or ATM-3507 in combination with paclitaxel in CHLA- 20 neuroblastoma cells; Figure S4. Cytotoxicity of CHLA-20 cells treated with different dosing regimens of TR100 plus VCR; Figure S5. Effect of combining TR100 and vincristine on tumor growth;Figure S6. Weights of animals from Fig. 4 and S5; Figure S7. The combination of tropomyosin inhibitors plus vincristine did not impact the microtubule network of cells in interphase; Figure S8. The combination of TR100 and paclitaxel induces apoptosis in CHLA-20 neuroblastoma cells; Table S1. IC50 concentrations for TR100 and ATM-3057 in a panel of neuroblastoma cell lines; Table S2. Pharmacokinetic analysis after single dosing of ATM3507/Dexolve intravenously at 30mg/kg in non-tumor bearing immunocompetent mice (Balb/C, n=3).
Supplementary Table 4 from A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity
Authors: Hu Sophia , Ueda Masumi , Stetson Lindsay , Ignatz-Hoover James , Moreton Stephen , Chakrabarti Amit , Xia Zhiqiang , Karan Goutam , de Lima Marcos , Agrawal Mukesh K. , Wald David N.
Published: April 2023

Microarray gene overlap
Supplementary Table 3 from A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity
Authors: Hu Sophia , Ueda Masumi , Stetson Lindsay , Ignatz-Hoover James , Moreton Stephen , Chakrabarti Amit , Xia Zhiqiang , Karan Goutam , de Lima Marcos , Agrawal Mukesh K. , Wald David N.
Published: April 2023

Microarray differential expression
Supplementary Figures 1-2 from Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer
Authors: Lu Jianfeng , McEachern Donna , Li Shunqiang , Ellis Matthew J. , Wang Shaomeng
Published: April 2023

Supplementary Figure 1. MI-77301 induces upregulation of MDM2, p53, p21, PUMA, and cleavage of PARP in WHIM18 tumor tissues; Supplementary Figure 2. Treatment by MI-77301 alone, Fulvestrant alone or the combination does not affect the body weight of tumor-bearing mice.
Supplementary Table 2 from A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity
Authors: Hu Sophia , Ueda Masumi , Stetson Lindsay , Ignatz-Hoover James , Moreton Stephen , Chakrabarti Amit , Xia Zhiqiang , Karan Goutam , de Lima Marcos , Agrawal Mukesh K. , Wald David N.
Published: April 2023

Kinase profiling
Supplementary Table 1 from A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity
Authors: Hu Sophia , Ueda Masumi , Stetson Lindsay , Ignatz-Hoover James , Moreton Stephen , Chakrabarti Amit , Xia Zhiqiang , Karan Goutam , de Lima Marcos , Agrawal Mukesh K. , Wald David N.
Published: April 2023

Primer sequences
Supplementary Figure 6 from A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity
Authors: Hu Sophia , Ueda Masumi , Stetson Lindsay , Ignatz-Hoover James , Moreton Stephen , Chakrabarti Amit , Xia Zhiqiang , Karan Goutam , de Lima Marcos , Agrawal Mukesh K. , Wald David N.
Published: April 2023

Heatmap of Z-scores of genes that are significantly dysregulated
Supplementary figure S5 from Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism
Authors: Wiedmer Tabea , Blank Annika , Pantasis Sophia , Normand Lea , Bill Ruben , Krebs Philippe , Tschan Mario P. , Marinoni Ilaria , Perren Aurel
Published: April 2023

Downregulation of autophagic flux in knockdown cells
Supplementary figure S4 from Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism
Authors: Wiedmer Tabea , Blank Annika , Pantasis Sophia , Normand Lea , Bill Ruben , Krebs Philippe , Tschan Mario P. , Marinoni Ilaria , Perren Aurel
Published: April 2023

Effect of combination treatment on microvessel density, classification and number of metastases
Supplementary Figure 4 from A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity
Authors: Hu Sophia , Ueda Masumi , Stetson Lindsay , Ignatz-Hoover James , Moreton Stephen , Chakrabarti Amit , Xia Zhiqiang , Karan Goutam , de Lima Marcos , Agrawal Mukesh K. , Wald David N.
Published: April 2023

GS87 does not lead to observable alterations in normal hematopoiesis
Supplementary Figure 3 from A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity
Authors: Hu Sophia , Ueda Masumi , Stetson Lindsay , Ignatz-Hoover James , Moreton Stephen , Chakrabarti Amit , Xia Zhiqiang , Karan Goutam , de Lima Marcos , Agrawal Mukesh K. , Wald David N.
Published: April 2023

ATRA leads to marked induction of CD11b in Acute Promyelocytic Cells
Supplementary Figure 2 from A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity
Authors: Hu Sophia , Ueda Masumi , Stetson Lindsay , Ignatz-Hoover James , Moreton Stephen , Chakrabarti Amit , Xia Zhiqiang , Karan Goutam , de Lima Marcos , Agrawal Mukesh K. , Wald David N.
Published: April 2023

Representative flow histograms showing CD11b staining of AML cells after GS87 treatment
Supplementary figure S1 from Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism
Authors: Wiedmer Tabea , Blank Annika , Pantasis Sophia , Normand Lea , Bill Ruben , Krebs Philippe , Tschan Mario P. , Marinoni Ilaria , Perren Aurel
Published: April 2023

Representative pictures of analyses on H&E staining
Supplemental Figure 1 from CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation
Authors: Wang Dan-Dan , Chen Ying , Chen Zi-Bo , Yan Fang-Jie , Dai Xiao-Yang , Ying Mei-Dan , Cao Ji , Ma Jian , Luo Pei-Hua , Han Yong-Xin , Peng Yong , Sun Ying-Hui , Zhang Hui , He Qiao-Jun , Yang Bo , Zhu Hong
Published: April 2023

The combination of cabozantinib and CT-707 imposed minimal synergistic cytotoxicity against the human hepatocyte HL-7702 cells.
Supplementary data: Figures 1-10 from Paclitaxel-Loaded Polymersomes for Enhanced Intraperitoneal Chemotherapy
Authors: Simón-Gracia Lorena , Hunt Hedi , Scodeller Pablo D. , Gaitzsch Jens , Braun Gary B. , Willmore Anne-Mari A. , Ruoslahti Erkki , Battaglia Giuseppe , Teesalu Tambet
Published: April 2023

Figure S1: Structure of the co-polymer POEGMA-PDPA; Figure S2: Quantification of paclitaxel loading into polymersomes (PS-PTX) and PTX release from the vesicles; Figure S3: z-potential measurements; Figure S4: In vitro cellular internalization and drug release of polymersomes; Figure S5: Viability and proliferation and of MKN-45P and CT-26 cells; Figure S6: Fluorescence in control organs; Figure S7: In vivo imaging of rhodamine-labeled polymersomes; Figure S8: Homing of fluorescein-labeled polymersomes to organs; Figure S9: Subcutaneous tumor homing of polymersomes; Figure S10: Peritoneal tumor homing of polymersomes after IP and IV injection.
Tables S1-S5 from The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+ Stem/Progenitor Cells
Authors: Murone Maximilien , Radpour Ramin , Attinger Antoine , Chessex Anne Vaslin , Huguenin Anne-Laure , Schürch Christian M. , Banz Yara , Sengupta Saumitra , Aguet Michel , Rigotti Stefania , Bachhav Yogeshwar , Massière Frédéric , Ramachandra Murali , McAllister Andres , Riether Carsten
Published: April 2023

Tables S1-S4 show patient characteristics, kinome scan for Debio 0617B, selectivitly profile, GI50 values and FLT3-ITD inhibition capacity of Debio 0617B.
Supplementary Methods and Materials from The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+ Stem/Progenitor Cells
Authors: Murone Maximilien , Radpour Ramin , Attinger Antoine , Chessex Anne Vaslin , Huguenin Anne-Laure , Schürch Christian M. , Banz Yara , Sengupta Saumitra , Aguet Michel , Rigotti Stefania , Bachhav Yogeshwar , Massière Frédéric , Ramachandra Murali , McAllister Andres , Riether Carsten
Published: April 2023

Supplementary methods and materials shows supplemental procedures.
Supplemental Figure 3 from Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398
Authors: Datta Jharna , Damodaran Senthilkumar , Parks Hannah , Ocrainiciuc Cristina , Miya Jharna , Yu Lianbo , Gardner Elijah P. , Samorodnitsky Eric , Wing Michele R. , Bhatt Darshna , Hays John , Reeser Julie W. , Roychowdhury Sameek
Published: April 2023

Morphological changes in BGJ398 resistant cell lines.
Figure S9 from The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+ Stem/Progenitor Cells
Authors: Murone Maximilien , Radpour Ramin , Attinger Antoine , Chessex Anne Vaslin , Huguenin Anne-Laure , Schürch Christian M. , Banz Yara , Sengupta Saumitra , Aguet Michel , Rigotti Stefania , Bachhav Yogeshwar , Massière Frédéric , Ramachandra Murali , McAllister Andres , Riether Carsten
Published: April 2023

Figure S9 shows that Debio 0617B reduces spleen weight and cellularity in human PDX AML mice.
Figure S7 from The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+ Stem/Progenitor Cells
Authors: Murone Maximilien , Radpour Ramin , Attinger Antoine , Chessex Anne Vaslin , Huguenin Anne-Laure , Schürch Christian M. , Banz Yara , Sengupta Saumitra , Aguet Michel , Rigotti Stefania , Bachhav Yogeshwar , Massière Frédéric , Ramachandra Murali , McAllister Andres , Riether Carsten
Published: April 2023

Figure S7 shows the CFU and re-plating capacity of CD34-positive stem/progenitor cells from healthy donors and newly diagnosed AML patients after exposure to Debio 0617B
Supplemental Figure 2 from Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398
Authors: Datta Jharna , Damodaran Senthilkumar , Parks Hannah , Ocrainiciuc Cristina , Miya Jharna , Yu Lianbo , Gardner Elijah P. , Samorodnitsky Eric , Wing Michele R. , Bhatt Darshna , Hays John , Reeser Julie W. , Roychowdhury Sameek
Published: April 2023

Chemical structures of inhibitors of FGFR (BGJ398) and Akt (GSK2141795).
Figure S6 from The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+ Stem/Progenitor Cells
Authors: Murone Maximilien , Radpour Ramin , Attinger Antoine , Chessex Anne Vaslin , Huguenin Anne-Laure , Schürch Christian M. , Banz Yara , Sengupta Saumitra , Aguet Michel , Rigotti Stefania , Bachhav Yogeshwar , Massière Frédéric , Ramachandra Murali , McAllister Andres , Riether Carsten
Published: April 2023

Figure S6 shows that the body weight of naive mice is not affected by Debio 0617B.
Supplemental Figure 1 from Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398
Authors: Datta Jharna , Damodaran Senthilkumar , Parks Hannah , Ocrainiciuc Cristina , Miya Jharna , Yu Lianbo , Gardner Elijah P. , Samorodnitsky Eric , Wing Michele R. , Bhatt Darshna , Hays John , Reeser Julie W. , Roychowdhury Sameek
Published: April 2023

FGFR 1 and FGFR3 expression in DMS114 and RT112 cell lines.
Figure S5 from The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+ Stem/Progenitor Cells
Authors: Murone Maximilien , Radpour Ramin , Attinger Antoine , Chessex Anne Vaslin , Huguenin Anne-Laure , Schürch Christian M. , Banz Yara , Sengupta Saumitra , Aguet Michel , Rigotti Stefania , Bachhav Yogeshwar , Massière Frédéric , Ramachandra Murali , McAllister Andres , Riether Carsten
Published: April 2023

Figure S5 shows the anti-leukemic activity of Debio 0617B in a MOLM-13-luciferase disseminated AML mouse model.
Figure S2 from The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+ Stem/Progenitor Cells
Authors: Murone Maximilien , Radpour Ramin , Attinger Antoine , Chessex Anne Vaslin , Huguenin Anne-Laure , Schürch Christian M. , Banz Yara , Sengupta Saumitra , Aguet Michel , Rigotti Stefania , Bachhav Yogeshwar , Massière Frédéric , Ramachandra Murali , McAllister Andres , Riether Carsten
Published: April 2023

Figure S2 shows Debio 0617B-induced apoptosis of the FLT3-ITD-driven AML cell line MOLM-13.
Figure S1 from The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+ Stem/Progenitor Cells
Authors: Murone Maximilien , Radpour Ramin , Attinger Antoine , Chessex Anne Vaslin , Huguenin Anne-Laure , Schürch Christian M. , Banz Yara , Sengupta Saumitra , Aguet Michel , Rigotti Stefania , Bachhav Yogeshwar , Massière Frédéric , Ramachandra Murali , McAllister Andres , Riether Carsten
Published: April 2023

Figure S1 shows expression of nuclear pSTAT3 and pSTAT5 in BM of newly diagnosed AML patients.
Supplementary Table 3 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Authors: Punnoose Elizabeth A. , Leverson Joel D. , Peale Franklin , Boghaert Erwin R. , Belmont Lisa D. , Tan Nguyen , Young Amy , Mitten Michael , Ingalla Ellen , Darbonne Walter C. , Oleksijew Anatol , Tapang Paul , Yue Peng , Oeh Jason , Lee Leslie , Maiga Sophie , Fairbrother Wayne J. , Amiot Martine , Souers Andrew J. , Sampath Deepak
Published: April 2023

BCL2, BCL2L1 and MCL1 mRNA in CD138 primary MM patient samples and sensitivity to veneteclax ex vivo
Supplementary Table 1 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Authors: Punnoose Elizabeth A. , Leverson Joel D. , Peale Franklin , Boghaert Erwin R. , Belmont Lisa D. , Tan Nguyen , Young Amy , Mitten Michael , Ingalla Ellen , Darbonne Walter C. , Oleksijew Anatol , Tapang Paul , Yue Peng , Oeh Jason , Lee Leslie , Maiga Sophie , Fairbrother Wayne J. , Amiot Martine , Souers Andrew J. , Sampath Deepak
Published: April 2023

qPCR primer sequences for Apopanel of BCL2 family members
Supplementary Figure 5 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Authors: Punnoose Elizabeth A. , Leverson Joel D. , Peale Franklin , Boghaert Erwin R. , Belmont Lisa D. , Tan Nguyen , Young Amy , Mitten Michael , Ingalla Ellen , Darbonne Walter C. , Oleksijew Anatol , Tapang Paul , Yue Peng , Oeh Jason , Lee Leslie , Maiga Sophie , Fairbrother Wayne J. , Amiot Martine , Souers Andrew J. , Sampath Deepak
Published: April 2023

BCL-2 and BCL-XL IHC correlates with qPCR and immunobot analysis of HMCLs
Supplementary Figure 4 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Authors: Punnoose Elizabeth A. , Leverson Joel D. , Peale Franklin , Boghaert Erwin R. , Belmont Lisa D. , Tan Nguyen , Young Amy , Mitten Michael , Ingalla Ellen , Darbonne Walter C. , Oleksijew Anatol , Tapang Paul , Yue Peng , Oeh Jason , Lee Leslie , Maiga Sophie , Fairbrother Wayne J. , Amiot Martine , Souers Andrew J. , Sampath Deepak
Published: April 2023

Conceptual workflow for establishing BCL-2 family IHC cut-offs for analysis of MM patient tumor samples
Supplementary Figure 3 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Authors: Punnoose Elizabeth A. , Leverson Joel D. , Peale Franklin , Boghaert Erwin R. , Belmont Lisa D. , Tan Nguyen , Young Amy , Mitten Michael , Ingalla Ellen , Darbonne Walter C. , Oleksijew Anatol , Tapang Paul , Yue Peng , Oeh Jason , Lee Leslie , Maiga Sophie , Fairbrother Wayne J. , Amiot Martine , Souers Andrew J. , Sampath Deepak
Published: April 2023

Caspase-dependent degradation of MCL-1 in NCI-H929 HMCL following treatment with bortezomib treatment
Supplementary Figure 4 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo
Authors: Staudacher Alexander H. , Li Yanrui , Liapis Vasilios , Hou Jeff Jia Cheng , Chin David , Dolezal Olan , Adams Timothy E. , van Berkel Patrick H. , Brown Michael P.
Published: April 2023

Dose escalation study of DAB4-MMAE and DAB4-Duocarmycin DM alone or in combination with chemotherapy in LL2 tumor model.
Supplementary Figure 2 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Authors: Punnoose Elizabeth A. , Leverson Joel D. , Peale Franklin , Boghaert Erwin R. , Belmont Lisa D. , Tan Nguyen , Young Amy , Mitten Michael , Ingalla Ellen , Darbonne Walter C. , Oleksijew Anatol , Tapang Paul , Yue Peng , Oeh Jason , Lee Leslie , Maiga Sophie , Fairbrother Wayne J. , Amiot Martine , Souers Andrew J. , Sampath Deepak
Published: April 2023

Immunoblots of BCL-2, BCL-XL and MCL-1 in HMCL tumor xenografts
Supplementary Figure 3 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo
Authors: Staudacher Alexander H. , Li Yanrui , Liapis Vasilios , Hou Jeff Jia Cheng , Chin David , Dolezal Olan , Adams Timothy E. , van Berkel Patrick H. , Brown Michael P.
Published: April 2023

Chemotherapy increases cathepsin B expression and macrophages in tumors.
Supplementary Data from Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction
Authors: Spasevska Ivana , Matera Eva Laure , Chettab Kamel , Ville Jade , Potier-Cartereau Marie , Jordheim Lars Petter , Thieblemont Catherine , Sahin Denis , Klein Christian , Dumontet Charles
Published: April 2023

Supplementary Figures
Table S2 from Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes In Vitro and In Vivo: Preclinical Studies as Guidance for Clinical Development and Trial Design
Authors: Sootome Hiroshi , Miura Akihiro , Masuko Norio , Suzuki Takamasa , Uto Yoshihiro , Hirai Hiroshi
Published: April 2023

Combination Index scores (CI50 and CI75) are shown in the indicated cell lines.
Fiugre S2 from Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes In Vitro and In Vivo: Preclinical Studies as Guidance for Clinical Development and Trial Design
Authors: Sootome Hiroshi , Miura Akihiro , Masuko Norio , Suzuki Takamasa , Uto Yoshihiro , Hirai Hiroshi
Published: April 2023

(a) Structure of compound #1. (b) IC50 value of compound #1 for each recombinant Aurora kinase. (c) Fold enhancement of GI50 of paclitaxel by compound #1 in HeLa cells. (d) Expression changes of SAC-related genes
Figure S4 from Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes In Vitro and In Vivo: Preclinical Studies as Guidance for Clinical Development and Trial Design
Authors: Sootome Hiroshi , Miura Akihiro , Masuko Norio , Suzuki Takamasa , Uto Yoshihiro , Hirai Hiroshi
Published: April 2023

Optimization of dosing schedule of TAS-119 HCl salt in combination with docetaxel in a xenograft model in mice.
Supplementary Data from Development of Tumor-Targeting IRE-1 Inhibitors for B-cell Cancer Therapy
Authors: Shao Andong , Xu Qin , Spalek Walker T. , Cain Christopher F. , Kang Chang Won , Tang Chih-Hang Anthony , Del Valle Juan R. , Hu Chih-Chi Andrew
Published: April 2023

Supplementary methods, table, figures and legends
Supplementary Data from Menin-mediated Repression of Glycolysis in Combination with Autophagy Protects Colon Cancer Against Small-molecule EGFR Inhibitors
Authors: Katona Bryson W. , Hojnacki Taylor , Glynn Rebecca A. , Paulosky Kayla E. , Szigety Katherine M. , Cao Yan , Zhang Xuyao , Feng Zijie , He Xin , Ma Jian , Hua Xianxin
Published: April 2023

Supplementary Figures 1-5
supplementary Figure 1 from A Novel Bispecific Antibody with PD-L1–assisted OX40 Activation for Cancer Treatment
Authors: Kuang Zhihui , Pu Pu , Wu Min , Wu Zhihai , Wang Li , Li Yiming , Zhang Shaofei , Jing Hua , Wu Weiwei , Chen Bingliang , Liu Junjian
Published: April 2023

Biophysical properties
Supplementary Data from RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity
Authors: Wang Hong , Ashton Reading , Hensel Jonathan A. , Lee Joo Hyoung , Khattar Vinayak , Wang Yong , Deshane Jessy S. , Ponnazhagan Selvarangan
Published: April 2023

Supplementary Table
Supplementary Figure 4 from A Novel Bispecific Antibody with PD-L1–assisted OX40 Activation for Cancer Treatment
Authors: Kuang Zhihui , Pu Pu , Wu Min , Wu Zhihai , Wang Li , Li Yiming , Zhang Shaofei , Jing Hua , Wu Weiwei , Chen Bingliang , Liu Junjian
Published: April 2023

Body weight change
Supplementary Tables from Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA TP53 Mutations—A Perspective from a Real-World Precision Medicine Cohort
Authors: Rosenberg Shai , Okamura Ryosuke , Kato Shumei , Soussi Thierry , Kurzrock Razelle
Published: April 2023

Supplementary Tables
Table S2 from Ion Channels and Their Role in the Pathophysiology of Gliomas
Authors: Takayasu Takeshi , Kurisu Kaoru , Esquenazi Yoshua , Ballester Leomar Y.
Published: April 2023

Ion channel expression in glioma
Table S2 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
Authors: Strickler John H. , LoRusso Patricia , Salgia Ravi , Kang Yoon-Koo , Yen Chia Jui , Lin Chia-Chi , Ansell Peter , Motwani Monica , Wong Shekman , Yue Huibin , Wang Lan , Reilly Edward , Afar Daniel , Naumovski Louie , Ramanathan Ramesh K.
Published: April 2023

Additional details for MET-amplified patients with one or more postbaseline tumor assessment (n=9).
Table S1 from Ion Channels and Their Role in the Pathophysiology of Gliomas
Authors: Takayasu Takeshi , Kurisu Kaoru , Esquenazi Yoshua , Ballester Leomar Y.
Published: April 2023

Ion channels and Sensitivity to Chemotherapy/Glioma Metabolism
Table S1 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
Authors: Strickler John H. , LoRusso Patricia , Salgia Ravi , Kang Yoon-Koo , Yen Chia Jui , Lin Chia-Chi , Ansell Peter , Motwani Monica , Wong Shekman , Yue Huibin , Wang Lan , Reilly Edward , Afar Daniel , Naumovski Louie , Ramanathan Ramesh K.
Published: April 2023

Additional details for TEAEs and TRAEs for all doses in the escalation cohort
Figure S2 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
Authors: Strickler John H. , LoRusso Patricia , Salgia Ravi , Kang Yoon-Koo , Yen Chia Jui , Lin Chia-Chi , Ansell Peter , Motwani Monica , Wong Shekman , Yue Huibin , Wang Lan , Reilly Edward , Afar Daniel , Naumovski Louie , Ramanathan Ramesh K.
Published: April 2023

CEA response over time in a 47-year-old patient with GEC responding to telisotuzumab
Supplementary Figure 5 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Authors: Thakkar Dipti , Sancenon Vicente , Taguiam Marvin M. , Guan Siyu , Wu Zhihao , Ng Eric , Paszkiewicz Konrad H. , Ingram Piers J. , Boyd-Kirkup Jerome D.
Published: April 2023

10D1P demonstrates potent in vivo tumor growth inhibition in multiple xenograft tumor models
Supplementary Figure 2 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Authors: Thakkar Dipti , Sancenon Vicente , Taguiam Marvin M. , Guan Siyu , Wu Zhihao , Ng Eric , Paszkiewicz Konrad H. , Ingram Piers J. , Boyd-Kirkup Jerome D.
Published: April 2023

10D1F interacts with linear peptides from the HER3 domain II dimerization interface
Supplementary Figure 1 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Authors: Thakkar Dipti , Sancenon Vicente , Taguiam Marvin M. , Guan Siyu , Wu Zhihao , Ng Eric , Paszkiewicz Konrad H. , Ingram Piers J. , Boyd-Kirkup Jerome D.
Published: April 2023

10D1F parental antibody, 10D1P, binds with high affinity and specificity to a species-conserved epitope on HER3, and Class 1 and Class 2 HER3 antibodies show different HER3 binding profiles in presence and absence of NRG1
Supplemental Table 3 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Authors: Thakkar Dipti , Sancenon Vicente , Taguiam Marvin M. , Guan Siyu , Wu Zhihao , Ng Eric , Paszkiewicz Konrad H. , Ingram Piers J. , Boyd-Kirkup Jerome D.
Published: April 2023

Supplemental Table 3 - Toxicological data showing no adverse effects of 10D1F on the indicated hematological and biochemistry parameters in multiple rodent models
Table S1 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
Authors: Xie Binbin , Wan Jianqin , Chen Xiaona , Han Weidong , Wang Hangxiang
Published: April 2023

Supplementary Table S1. Hematology measurements for the mice after the treatment with saline, cabazitaxel and dCTX NPs. The blood samples were collected on day 0, 6, 11, and 15 post-administration. The data are presented as the means {plus minus} SD (n = 5).
Supplementary Methods from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
Authors: Xie Binbin , Wan Jianqin , Chen Xiaona , Han Weidong , Wang Hangxiang
Published: April 2023

Supplementary methods for nanonparticle characterization, cell assays and histological analyses of tumors.
Figure S3 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
Authors: Xie Binbin , Wan Jianqin , Chen Xiaona , Han Weidong , Wang Hangxiang
Published: April 2023

Supplementary Figure S3. The cytotoxicity of dCTX NPs compared with cabazitaxel against cancer cell lines in vitro. Analysis (A) and quantification (B) of cell cycle of HeLa and A549 cells after the treatment with dCTX NPs for 48 h. The drug concentrations used to treat HeLa and A549 cells were 8 and 2 nM, respectively.
Figure S2 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
Authors: Xie Binbin , Wan Jianqin , Chen Xiaona , Han Weidong , Wang Hangxiang
Published: April 2023

Supplementary Figure S2. The cytotoxicity of dCTX NPs compared with cabazitaxel against cancer cell lines in vitro. Analysis (A) and quantification (B) of apoptosis of HeLa and A549 cells after the treatment with dCTX NPs for 48 h. The drug concentrations used to treat HeLa and A549 cells were 16 and 4 nM, respectively.
Figure S1 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
Authors: Xie Binbin , Wan Jianqin , Chen Xiaona , Han Weidong , Wang Hangxiang
Published: April 2023

Supplementary Figure S1. Chemical structures of paclitaxel, docetaxel, and cabazitaxel.
Supplementary Table 3 from Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Authors: Pucciarelli Daniela , Angus Steven P. , Huang Benjamin , Zhang Chi , Nakaoka Hiroki J. , Krishnamurthi Ganesh , Bandyopadhyay Sourav , Clapp D. Wade , Shannon Kevin , Johnson Gary L. , Nakamura Jean L.
Published: April 2023

Supplementary Table 3
Supplementary Table 2 from Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Authors: Pucciarelli Daniela , Angus Steven P. , Huang Benjamin , Zhang Chi , Nakaoka Hiroki J. , Krishnamurthi Ganesh , Bandyopadhyay Sourav , Clapp D. Wade , Shannon Kevin , Johnson Gary L. , Nakamura Jean L.
Published: April 2023

Supplementary Table 2
Supplementary Materials and Methods from Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Authors: Pucciarelli Daniela , Angus Steven P. , Huang Benjamin , Zhang Chi , Nakaoka Hiroki J. , Krishnamurthi Ganesh , Bandyopadhyay Sourav , Clapp D. Wade , Shannon Kevin , Johnson Gary L. , Nakamura Jean L.
Published: April 2023

Supplementary Materials and Methods
Fig. S8 from Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Authors: Pucciarelli Daniela , Angus Steven P. , Huang Benjamin , Zhang Chi , Nakaoka Hiroki J. , Krishnamurthi Ganesh , Bandyopadhyay Sourav , Clapp D. Wade , Shannon Kevin , Johnson Gary L. , Nakamura Jean L.
Published: April 2023

Supplementary Figure 8
Supplementary Data from Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer
Authors: Rogers Oliver C. , Antony Lizamma , Levy Oren , Joshi Nitin , Simons Brian W. , Dalrymple Susan L. , Rosen D. Marc , Pickering Andrew , Lan Haoyue , Kuang Heidi , Ranganath Sudhir H. , Zheng Lei , Karp Jeffrey M. , Howard S. Peter , Denmeade Samuel R. , Isaacs John T. , Brennen W. Nathaniel
Published: April 2023

Suppl Methods
Supplementary Data TS5 from Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer
Authors: Rogers Oliver C. , Antony Lizamma , Levy Oren , Joshi Nitin , Simons Brian W. , Dalrymple Susan L. , Rosen D. Marc , Pickering Andrew , Lan Haoyue , Kuang Heidi , Ranganath Sudhir H. , Zheng Lei , Karp Jeffrey M. , Howard S. Peter , Denmeade Samuel R. , Isaacs John T. , Brennen W. Nathaniel
Published: April 2023

Tbl S5
Fig. S1 from Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Authors: Pucciarelli Daniela , Angus Steven P. , Huang Benjamin , Zhang Chi , Nakaoka Hiroki J. , Krishnamurthi Ganesh , Bandyopadhyay Sourav , Clapp D. Wade , Shannon Kevin , Johnson Gary L. , Nakamura Jean L.
Published: April 2023

Supplementary Figure 1
Supplementary Data TS3 from Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer
Authors: Rogers Oliver C. , Antony Lizamma , Levy Oren , Joshi Nitin , Simons Brian W. , Dalrymple Susan L. , Rosen D. Marc , Pickering Andrew , Lan Haoyue , Kuang Heidi , Ranganath Sudhir H. , Zheng Lei , Karp Jeffrey M. , Howard S. Peter , Denmeade Samuel R. , Isaacs John T. , Brennen W. Nathaniel
Published: April 2023

Tbl S3
Figure S3 from Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer
Authors: Rogers Oliver C. , Antony Lizamma , Levy Oren , Joshi Nitin , Simons Brian W. , Dalrymple Susan L. , Rosen D. Marc , Pickering Andrew , Lan Haoyue , Kuang Heidi , Ranganath Sudhir H. , Zheng Lei , Karp Jeffrey M. , Howard S. Peter , Denmeade Samuel R. , Isaacs John T. , Brennen W. Nathaniel
Published: April 2023

Fig. S3
Figure S2 from Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer
Authors: Rogers Oliver C. , Antony Lizamma , Levy Oren , Joshi Nitin , Simons Brian W. , Dalrymple Susan L. , Rosen D. Marc , Pickering Andrew , Lan Haoyue , Kuang Heidi , Ranganath Sudhir H. , Zheng Lei , Karp Jeffrey M. , Howard S. Peter , Denmeade Samuel R. , Isaacs John T. , Brennen W. Nathaniel
Published: April 2023

Fig. S2
Figure S1 from Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer
Authors: Rogers Oliver C. , Antony Lizamma , Levy Oren , Joshi Nitin , Simons Brian W. , Dalrymple Susan L. , Rosen D. Marc , Pickering Andrew , Lan Haoyue , Kuang Heidi , Ranganath Sudhir H. , Zheng Lei , Karp Jeffrey M. , Howard S. Peter , Denmeade Samuel R. , Isaacs John T. , Brennen W. Nathaniel
Published: April 2023

Fig. S1
Video E from Preclinical Development of MGC018, a Duocarmycin-based Antibody–drug Conjugate Targeting B7-H3 for Solid Cancer
Authors: Scribner Juniper A. , Brown Jennifer G. , Son Thomas , Chiechi Michael , Li Pam , Sharma Sharad , Li Hua , De Costa Anushka , Li Ying , Chen Yan , Easton Ann , Yee-Toy Nicholas C. , Chen Francine Z. , Gorlatov Sergey , Barat Bhaswati , Huang Ling , Wolff Christina R. , Hooley Jeff , Hotaling Tim E. , Gaynutdinov Timur , Ciccarone Valentina , Tamura James , Koenig Scott , Moore Paul A. , Bonvini Ezio , Loo Deryk
Published: April 2023

Co-culture of 5000 Hs700T parental cells and 5000 Hs700T B7-H3 KO/RFP cells in the presence of 6.7 nM MGC018
Video C from Preclinical Development of MGC018, a Duocarmycin-based Antibody–drug Conjugate Targeting B7-H3 for Solid Cancer
Authors: Scribner Juniper A. , Brown Jennifer G. , Son Thomas , Chiechi Michael , Li Pam , Sharma Sharad , Li Hua , De Costa Anushka , Li Ying , Chen Yan , Easton Ann , Yee-Toy Nicholas C. , Chen Francine Z. , Gorlatov Sergey , Barat Bhaswati , Huang Ling , Wolff Christina R. , Hooley Jeff , Hotaling Tim E. , Gaynutdinov Timur , Ciccarone Valentina , Tamura James , Koenig Scott , Moore Paul A. , Bonvini Ezio , Loo Deryk
Published: April 2023

5000 Hs700T parental cells only in the presence of 6.7 nM MGC018
Video B from Preclinical Development of MGC018, a Duocarmycin-based Antibody–drug Conjugate Targeting B7-H3 for Solid Cancer
Authors: Scribner Juniper A. , Brown Jennifer G. , Son Thomas , Chiechi Michael , Li Pam , Sharma Sharad , Li Hua , De Costa Anushka , Li Ying , Chen Yan , Easton Ann , Yee-Toy Nicholas C. , Chen Francine Z. , Gorlatov Sergey , Barat Bhaswati , Huang Ling , Wolff Christina R. , Hooley Jeff , Hotaling Tim E. , Gaynutdinov Timur , Ciccarone Valentina , Tamura James , Koenig Scott , Moore Paul A. , Bonvini Ezio , Loo Deryk
Published: April 2023

5000 Hs700T B7-H3 KO/RFP cells only without treatment
Supplementary Materials and Methods from Preclinical Development of MGC018, a Duocarmycin-based Antibody–drug Conjugate Targeting B7-H3 for Solid Cancer
Authors: Scribner Juniper A. , Brown Jennifer G. , Son Thomas , Chiechi Michael , Li Pam , Sharma Sharad , Li Hua , De Costa Anushka , Li Ying , Chen Yan , Easton Ann , Yee-Toy Nicholas C. , Chen Francine Z. , Gorlatov Sergey , Barat Bhaswati , Huang Ling , Wolff Christina R. , Hooley Jeff , Hotaling Tim E. , Gaynutdinov Timur , Ciccarone Valentina , Tamura James , Koenig Scott , Moore Paul A. , Bonvini Ezio , Loo Deryk
Published: April 2023

Supplementary Materials and Methods
Supplementary Data from Preclinical Development of MGC018, a Duocarmycin-based Antibody–drug Conjugate Targeting B7-H3 for Solid Cancer
Authors: Scribner Juniper A. , Brown Jennifer G. , Son Thomas , Chiechi Michael , Li Pam , Sharma Sharad , Li Hua , De Costa Anushka , Li Ying , Chen Yan , Easton Ann , Yee-Toy Nicholas C. , Chen Francine Z. , Gorlatov Sergey , Barat Bhaswati , Huang Ling , Wolff Christina R. , Hooley Jeff , Hotaling Tim E. , Gaynutdinov Timur , Ciccarone Valentina , Tamura James , Koenig Scott , Moore Paul A. , Bonvini Ezio , Loo Deryk
Published: April 2023

Supplementary Data
Supplementary Data from Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer
Authors: Kim Mark Seungwook , Ma Shaolin , Chelariu-Raicu Anca , Leuschner Carola , Alila Hector W. , Lee Sanghoon , Coleman Robert L. , Sood Anil K.
Published: April 2023

Supplementary data
Figure S3 from Polyamine Blocking Therapy Decreases Survival of Tumor-Infiltrating Immunosuppressive Myeloid Cells and Enhances the Antitumor Efficacy of PD-1 Blockade
Authors: Alexander Eric T. , Mariner Kelsey , Donnelly Julia , Phanstiel Otto , Gilmour Susan K.
Published: April 2023

Supplementary Figure/Legend S3
Figure S2 from Polyamine Blocking Therapy Decreases Survival of Tumor-Infiltrating Immunosuppressive Myeloid Cells and Enhances the Antitumor Efficacy of PD-1 Blockade
Authors: Alexander Eric T. , Mariner Kelsey , Donnelly Julia , Phanstiel Otto , Gilmour Susan K.
Published: April 2023

Supplementary Figure/Legend S2
Figure S1 from Polyamine Blocking Therapy Decreases Survival of Tumor-Infiltrating Immunosuppressive Myeloid Cells and Enhances the Antitumor Efficacy of PD-1 Blockade
Authors: Alexander Eric T. , Mariner Kelsey , Donnelly Julia , Phanstiel Otto , Gilmour Susan K.
Published: April 2023

Supplementary Figure/Legend S1
Table S1 from PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation
Authors: Michmerhuizen Anna R. , Pesch Andrea M. , Moubadder Leah , Chandler Benjamin C. , Wilder-Romans Kari , Cameron Meleah , Olsen Eric , Thomas Dafydd G. , Zhang Amanda , Hirsh Nicole , Ritter Cassandra L. , Liu Meilan , Nyati Shyam , Pierce Lori J. , Jagsi Reshma , Speers Corey
Published: April 2023

Extended methods for immunohistochemistry. Antibodies used in immunohistochemistry experiments are listed with each of the corresponding dilutions, retrieval techniques, and positive controls.